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Abstract
Background: Recent studies have shown that DNA methylation (DNAm) markers in peripheral blood may hold promise as
diagnostic or early detection/risk markers for epithelial cancers. However, to date no study has evaluated the diagnostic and
predictive potential of such markers in a large case control cohort and on a genome-wide basis.
Principal Findings: By performing genome-wide DNAm profiling of a large ovarian cancer case control cohort, we here
demonstrate that active ovarian cancer has a significant impact on the DNAm pattern in peripheral blood. Specifically, by
measuring the methylation levels of over 27,000 CpGs in blood cells from 148 healthy individuals and 113 age-matched pre-
treatment ovarian cancer cases, we derive a DNAm signature that can predict the presence of active ovarian cancer in blind
test sets with an AUC of 0.8 (95% CI (0.74–0.87)). We further validate our findings in another independent set of 122 post-
treatment cases (AUC=0.76 (0.72–0.81)). In addition, we provide evidence for a significant number of candidate risk or early
detection markers for ovarian cancer. Furthermore, by comparing the pattern of methylation with gene expression data
from major blood cell types, we here demonstrate that age and cancer elicit common changes in the composition of
peripheral blood, with a myeloid skewing that increases with age and which is further aggravated in the presence of ovarian
cancer. Finally, we show that most cancer and age associated methylation variability is found at CpGs located outside of
CpG islands.
Significance: Our results underscore the potential of DNAm profiling in peripheral blood as a tool for detection or risk-
prediction of epithelial cancers, and warrants further in-depth and higher CpG coverage studies to further elucidate this
role.
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Introduction
The role of epigenetics in cancer and other common complex
diseases is undisputed [1,2]. A unique facet of epigenetic marks
that distinguishes them from their genetic counterparts, is their
sensitivity to undergo alterations in response to dietary and other
environmental exposures [1,3,4]. Given the epidemiological link
between environmental factors and cancer it is natural to
hypothesize that epigenetic mutations acquired during an
individual’s life, predispose the individual to the disease [1,5–8].
Such a model is further supported by monozygotic twin studies
that point to age and environmentally related epigenetic
divergence as the cause of discordant disease status [9,10]. Thus,
it seems plausible that epigenetic changes associated with the
environment and aging may themselves be related to cancer [11],
and specifically that a number of these epigenetic mutations may
constitute cancer predisposition markers.
More recently, DNA methylation (DNAm) of specific genes
(SEPT9, RASSF1A, APC) in serum DNA have been proposed as
diagnostic and prognostic biomarkers for colorectal cancer [12,13]
and breast cancer [14], respectively. DNA methylation (DNAm)
changes associated with cancer and aging have also been observed
in peripheral blood samples from postmenopausal women [15,16].
Specifically, it has been suggested that known epidemiological risk
factors (e.g high hormone levels) may leave DNAm imprints in
peripheral blood DNA and that early detection of these marks
could be used to predict the future risk of an individual developing
cancer [15]. However, whether DNAm markers derived from
peripheral blood may serve as diagnostic or risk-prediction tools
remains controversial [17] and no study has yet evaluated their
clinical potential on a genome-wide basis.
We performed genome-wide DNAm profiling of peripheral
blood samples from a large ovarian cancer case-control cohort to
help address the following questions. First, what effect does the
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blood, a tissue that is unrelated to the cell of origin of an epithelial
cancer, and more specifically, can the presence of cancer be
predicted from the DNAm profile in blood? Second, can we
identify methylation markers in blood that may serve as early
detection or predisposition markers for ovarian cancer? Identifi-
cation of reliable diagnostic or early detection biomarkers derived
from blood is of great clinical and biological significance, specially
for ovarian cancer where early detection is difficult [18]. Finally,
following recent reports that most methylation variable positions
are located outside of CpG-islands [19], we explored the genomic
pattern of methylation variable positions in relation to CpG
density.
Results
Age and Cancer Related DNA Methylation Patterns
All 540 peripheral blood samples were hybridised to 27 k
Human Methylation Infinium beadchip arrays [20] (Materials and
Methods, Table S1). A stringent quality control and inter-array
normalisation procedure was used to remove confounding
variation due to experimental factors, resulting in a normalised
data matrix of methylation scores (b-values, 0,b,1) across 383
samples (148 healthy, 113 pre-treatment (preT) ovarian cancer
cases, 122 post-treatment (posT) ovarian cancer cases) and 25,642
CpG sites (Materials and Methods, Figure S1). Singular value
decomposition (SVD) of the normalised data demonstrated at least
10 significant components of variation with the largest components
associated with phenotypic factors, notably presence of cancer and
age (Figure S2, Materials and Methods).
A DNA Methylation Signature Associated with Ovarian
Cancer
We adopted a supervised approach to derive a cancer specific
DNA methylation signature and to ask whether such a signature
could be used to predict the disease status of blind test samples.
Specifically, we argued that tumor presence may have a large
enough impact on DNA methylation patterns that it ought to be
detectable from peripheral blood samples in patients prior to
undergoing treatment.
To ensure that results were not biased to a specific choice of
training/test set partition, we performed a total of 100 runs, each
run using a different training/test set partition (Materials and
Methods). For each choice of training set (90 controls and 70 preT
samples), we used a multivariate logistic regression model
(MVLR), with the CpG specific methylation profile as a predictor
and including BSC (bi-sulphite conversion) efficiency, DNA input
and batch effect as potentially confounding factors, to derive a p-
value of association with case control status for each of the 25,642
CpG sites (Materials and Methods). Next, CpG sites were ranked
according to their p-values and a shrunken centroid classifier
trained on the top 1000 CpG sites (FDR,0.05, Materials and
Methods). We observed that for the great majority of 100 runs,
optimal (or close to optimal) classifier performance in internal
cross-validations was obtained by selecting the top 100 CpG sites.
Finally, in each run, the resulting top 100 CpG classifier was
evaluated in a blind test set consisting of 58 healthy controls and
43 preT cases. Classifier performance on the training and test sets
was evaluated by means of ROC curves and associated AUC
(Figure 1a–b). Over the 100 runs, the mean AUC and 95%CI in
the training and test sets was 0.82 (0.78–0.85) and 0.80 (0.74–
0.87), respectively, indicating that the derived classifiers retained
strong predictive power in the blind test sets (Figure 1a–b).
Next, we investigated whether the derived classifiers could
predict cancer status of post-treatment samples with evidence of
active disease (determined by CA125 serum levels .30) at the time
of sample draw (47 samples). Averaged over the 100 runs, we
obtained an AUC of 0.76 (0.72–0.81, 95%CI) in blind test sets
consisting of 58 healthy controls and the (fixed) 47 postreatment
samples (Figure 1c). Significant power to discriminate post-
treatment samples with active disease from those without was also
attained (AUC=0.74, P,0.001). These results therefore con-
firmed the ability of the derived classifiers to predict the presence
of tumors in post-treatment samples. In contrast, the classifiers did
not predict the cancer status of post-treatment samples without
evidence of active disease (70 samples) relative to healthy controls
(AUC=0.52 (0.48–0.55, 95%CI)).
Next, we asked whether the classification performance could be
affected by age. To address this, we compared the ranking of the
CpG sites in the supervised MVLR analysis with the correspond-
ing ranking in a MVLR model that included age as a co-factor.
This showed that p-values of association were largely unchanged
and that both rankings were highly correlated (Spearman rank
correlation=0.998, Figure 1d), showing that the CpG sites on
which our classification was based were predictive of cancer status
independently of age.
Cancer Diagnostic CpGs (CA-CpGs)
Having established that a DNA methylation signature from
peripheral blood could be used to predict the presence of ovarian
cancer, we next used all the healthy controls and pre-treatment
samples to derive a final list of such ‘‘cancer diagnostic’’ CpGs
(CA-CpGs).
We identified a total of 2714 CA-CpGs passing an FDR
threshold of 0.05 (Figure 2a, Table S2, Figure S3). We observed a
skew towards hypomethylation with 1513 (56%) CA-CpGs
showing lower levels of methylation in cases (Figure 2a, Binomial
test P=9 610
210). Even more strikingly, for the top 50 CpGs (47
unique gene loci), 41 (87%) were hypomethylated (Binomial test
P=10
28, Table S2). Of the 2714 CA-CpGs, 1482 (55%) and 1232
(45%) were located within (iCpGs) and outside (niCpGs) CpG
islands [21], respectively. Given the overrepresentation of iCpGs
on the array (76% iCpGs vs 24% niCpGs), the number of niCpGs
associated with cancer was much higher than that expected by
chance (Figure 2a, Fisher test P,2e
216). The overrepresentation of
niCpGs among CA-CpGs was also evident from inspection of the
top 47 CA-CpG gene loci with 32 (68%) localised to niCpGs
(Fisher test P=6 610
212).
To further validate the diagnostic nature of the 2714 CpGs, we
evaluated their overlap with the 520 CpGs discriminating post-
treatment samples with and without active ovarian cancer
(FDR,0.05, data not shown). This yielded an overlap of 355
CpGs (Fisher test P,2610
216), confirming that effectively the
same cancer diagnostic DNA methylation signature could have
been derived in the post-treatment setting using CA125 levels as
markers of tumour presence.
Biological Significance of DNAm Signatures
To investigate the potential functional significance of the CA-
CpG set we asked if there was specific enrichment of biological
terms and pathways, including a large database of functional gene
expression signatures [22]. Recently, we showed that aging also
has a significant impact on the DNAm pattern of peripheral blood
and identified 589 CpGs significantly associated with age
(FDR,0.05) [16]. Thus, in order to dissect the roles of age and
cancer we performed Gene Set Enrichment Analysis (GSEA) [22]
on CpGs uniquely associated with age and cancer, as well as on
Peripheral Blood Methylation
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CpG lists (Figure 2b, Table S2). We note that this overlap was
highly significant (Figure 2b, Fisher test P,2610
216), suggesting
that age and tumor presence elicit common changes in the DNAm
pattern of peripheral blood. GSEA revealed functional associa-
tions (adjusted P,0.05) of four main categories of genes (Figure 2c,
Table S3): (i) REST-targets and developmental genes [23,24] with
hypermethylated age-CpGs, (ii) genes involved in hematopoiesis
and lymphoid-myeloid differentiation with hypomethylated age
and age-CA CpGs, (iii) genes involved in T-cell activation and
natural-killer (NK) mediated cytotoxicity with hypermethylated
cancer-specific CpGs, and (iv) genes involved in cell-adhesion and
HOXA9 regulatory programs with hypomethylated cancer-specific
CpGs.
Figure 1. Prediction of tumor presence by a DNAm signature in blood. a–b) Classification performance of DNA methylation classifiers in a)
training sets and b) blind test sets. Training and test sets consisted of blood samples from pre-treatment cases and healthy individuals (Materials and
Methods). Average ROC curve over 100 different training/test set partitions with 95% CI envelope in blind test sets. Mean AUC and 95% CI over 100
different partitions are given. c) Classification performance in test sets consisting of healthy controls and post-treatment samples with evidence of
active disease. d) Correlation between the ranking of top CpGs discriminating pre-treatment cases from healthy controls in regression models that
included age (x-axis) and without age (y-axis) as a co-factor. Plotted are the log10(p-values) for the 25,642 CpG sites, as evaluated from multiple
logistic regressions of case/control status against the CpG methylation profile with age as a co-factor (x-axis) and without age as a co-factor (y-axis).
Spearman correlation between the two rankings is given.
doi:10.1371/journal.pone.0008274.g001
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that some of these may reflect variations in blood cell type
composition, as this is known to vary with both age and tumor
presence [25–29]. To investigate this further, we asked if genes
known to be differentially expressed between main blood cell
types [30] were overrepresented in the age and CA-CpG lists.
Figure 2. Cancer and age CpGs, and GSEA. a) Distribution of 2,714 CA-CpGs (FDR,0.05) in terms of hyper-and-hypomethylation (Binomial test
P-value given), as well in relation to CpG localisation (Fisher’s exact test). b) Overlap of age-CpGs with CA-CpGs (Fisher-test P-value of overlap given)
and distribution of the 198 common age and CA-CpGs in terms of hypermethylated and hypomethylated patterns and iCpGs/niCpGs (Binomial and
Fisher-test P-values are given, respectively). Out of the 198 CpGs, 47 exbited hypermethylation with age and cancer, 150 hypomethylation with age
and cancer, 1 hyperM with age and hypoM with cancer and 0 showed hypoM with age and hypeM in cancer. c) Gene Set Enrichment Analysis for the
common age CA-CpGs, age-specific CpGs (i.e age CpGs minus CA-CpGs) and CA-specific CpGs (i.e CA-CpGs minus age-CpGs) stratified according to
hyper/hypometylation. Benjamini-Hochberg adjusted P-values are given. Most significantly enriched biological terms are given.
doi:10.1371/journal.pone.0008274.g002
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pronounced for the cancer than the age-associated signatures
(Table 1). Specifically, among CpGs hypomethylated in cancer
cases, there was enrichment of genes known to be upregulated in
granulocytes (P=2 610
25, Table 1), while CpGs hypermethy-
lated in cancer were enriched for genes known to be upregulated
in T-cell lymphocytes (CD4+ P=0.002, CD8+ P=0.01,Table1,
Table S4), consistent with reports of a higher granulocyte/
lymphocyte ratio in the blood of cancercases compared to healthy
controls [26,29]. To test this further we compared methylation
levels of those CpGs mapping to genes upregulated in granulo-
cytes and lmphocytes between healthy controls and post-
treatment cases with and without active disease (as determined
by CA125 levels) (Figure S4). As expected, genes upregulated in
granulocytes were significantly hypomethylated in post-treatment
cases with positive CA125 levels relative to controls, while this was
not so for post-treatment cases without active disease (Figure S4).
Similarly, genes upregulated in lmphocytes were significantly
hypermethylated in post-treatment cases with positive CA125
levels relative to controls, while there was no difference when
comparing post-treatmant cases without active disease to controls
(Figure S4).
Age-Dependent DNAm Signature Predicts Tumor
Presence
The strong overlap between the age and cancer associated
CpGs and the functional enrichment of genes involved in myeloid-
lymphoid differentiation indicated to us that age and cancer cause
the same changes in DNAm patterns by independently eliciting
the same underlying changes in blood cell type composition. We
therefore hypothesized that age-specific DNAm changes may be
aggravated in patients with ovarian cancer. To test this, we first
computed average methylation levels over CpGs undergoing
specific hyper or hypomethylation with age. These patterns
showed the expected correlations with age in healthy controls
and pretreatment cancer cases (Figures 3a,c,e,g & Figure S5).
However, we also observed that the average methylation values
were significantly different between pretreatment cases and
controls, with lower average methylation in cases versus controls
for age hypomethylated niCpGs (Figure 3b, Wilcox test
P=1 610
213) and iCpGs (Figure 3f, P=1 610
211), and corre-
spondingly higher average methylation levels in cases compared to
controls for niCpGs hypermethylated with age (Figure 3d,
P=3 610
216). Importantly, these associations with disease status
were independent of age group for the hypomethylated niCpGs
and iCpGs (Figures 3a,e). For the hypermethylated age CpGs, we
observed a corresponding pattern of hypermethylation in cancer in
all age groups for niCpGs (Figure 3c), but not so for iCpGs
(Figures 3g,h).
To further demonstrate that age-related DNAm patterns were
independently associated with tumor presence, we asked if the age
associated CpGs derived from the 148 healthy controls (293 CpGs
with FDR,0.3) [16] were able to discriminate samples according
to disease status (Figure 4a). Unsupervised hierarchical clustering
over the 293 CpGs segregated cases from controls (Figure 4b,
Fisher test P=4 610
213) .T h es a m ea g e - C p G sw e r ea l s oa b l et o
discriminate cases with recurrent active disease from those
without (as measured by serum CA125 levels at sample draw) in
an independent set of blood samples from 122 post-treatment
cases (Figure 4c, Fisher test P=3 610
25). To further establish the
significance of these findings, in none of 1000 random selections
of 293 CpGs did we observe P-values as extreme as these
(Figure 4d).
Cancer-Predisposition CpGs
It is plausible that a small number of the 2714 CA-CpGs are
bona-fide cancer-predisposition markers. We hypothesized that
some of these risk markers might be detectable from the 70 post-
treatment peripheral blood samples of patients who did not have
recurrent disease at the time of sample draw but who could
eventually develop recurrent disease, since such samples might
mimick the pre-clinical predisposition stage. To determine
rigorously whether such a risk CpG signature exists, we applied
a state-of-the-art Surrogate Variable Analysis (SVA) [31,32]
framework, which models hidden and potentially confounding
factors to obtain a more accurate estimate for the FDR (Materials
and Methods). Using SVA we obtained 84 CpGs passing a FDR
threshold of 0.4, suggesting that on average about 50 CpGs may
be discriminatory between post-treatment samples without active
disease (CA125 serum levels ,30) and healthy controls (Figure
S6a, Table S5). Since it is possible that some of these reflect
methylation changes due to treatment and since a risk CpG should
also be diagnostic, we deconvoluted the effect of treatment by
finding the overlap between the 84 CpGs and the 2714 CA-CpGs
(unaffected by treatment), which yielded an overlap of 18 ‘‘cancer-
predisposition’’ risk CpGs (Fisher test P=0.003, Figure S6b, Table
S5). Of interest, this list included TSG101, a gene with putative
tumour suppressor roles and a candidate breast cancer predispo-
sition gene [33].
Discussion
Here we have performed the first large scale (over 300 samples)
genome-wide study of DNAm profiles using a state-of-the art
platform that measures the methylation state of over 27,000 CpGs.
We have shown that ovarian cancer has a significant impact on the
DNAm pattern of peripheral blood cells. While the epigenetic
signature we have presented still lacks the high specificity
necessary for an immediate diagnostic application, the fact that
active ovarian cancer could be predicted with a relative high
accuracy (AUC=0.8) from a DNAm profile in blood clearly
demonstrates the future potential of epigenetic profiling as a
diagnostic tool.
In addition, we provided evidence for the existence of DNAm
markers that may serve as early detection or predisposition
markers for ovarian cancer. Of the 18 candidate risk markers, 11
and 7 showed hyper and hypomethylation in cancer, respectively,
with TSG101 and the pre-mRNA splicing factor SFRS6 both
undergoing hypermethylation in cancer. Further confirmation that
the markers identified here may serve as early detection or
predisposition markers for ovarian cancer will require a large
prospective study, which is currently ongoing [34].
The observed DNAm patterns can be summarised in terms of two
biologically distinct signatures. First, the observation that a DNAm
signatureforaging,characterisedbydifferentialmethylationofgenes
with hematopoietic cell lineage and immune system functions is
aggravated in the presence of ovarian cancer, suggests that an
epithelial tumour and aging elicit common changes in the cellular
composition of peripheral blood. This interpretation is further
supported by the fact that the same biological terms were strongly
enriched among genes differentially expressed between blood cell
types [30] (Table S6), and that genes commonly upregulated in
granulocytes and lymphocytes showed a differential methylation
pattern(Table1,Figure S4) consistent with an increased granulocyte
to lymphocyte ratio in response to aging or cancer. It is significant
that there is independent evidence that both aging and cancer
presence lead to a myeloid-skewing in the myeloid/lymphoid
differentiation program, with a corresponding higher granulocyte/
Peripheral Blood Methylation
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that granulocyte and T-lymphocyte specific genes were enriched
among CpGs hypo-and hypermethylated in cancer, respectively.
Since this effect was inferred from DNAm profiles, it would appear
that the expression of a substantial number of genes characterising
bood cell types is under direct epigenetic regulation.
Figure 3. Age-dependent methylation patterns are associated with ovarian cancer. Average methylation patterns of age-associated CpGs
selected through supervised analysis. (a–b) age hypomethylated niCpGs. (c–d) age hypermethylated niCpGs. (e–f) age hypomethylated iCpGs. (g–h)
age hypermethylated iCpGs. (a,c,e,g) Average methylation (y-axis) of controls (green) and cases (blue) for each of the six age groups (x-axis) (50–
55,55–60,60–65,65–70,70–75,.75). (b,d,f,h) Average methylation versus disease status (all age groups combined). All P-values are from a two-tailed
Wilcoxon rank sum test. In all panels, we give the numbers of samples in each group above the corresponding boxplot. Cases are pre-treatment
samples.
doi:10.1371/journal.pone.0008274.g003
Peripheral Blood Methylation
PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8274Figure 4. Clustering of samples over age-associated CpGs. a) Multivariate linear regression of age in 148 healthy blood samples against CpG
methylation profiles adjusting for BSC efficiency, batch and DNA input effects, identified 293 CpGs at q(FDR),0.3. b) Hierarchical clustering of the 148
healthy controls and 113 pre-treatment (preT) cases over the 293 CpGs. The two main clusters (CLUST) predicted by the algorithm are labelled as blue
and orange. Case control status is indicated as active disease (AD): case=black, control=grey. c) Hierarchical clustering of 117 post-treatment cases
over same 293 CpGs. Of the 117 post-treatment cases, 47 and 70 had recurrent (black) and no recurrent (grey) active disease (AD) at sample draw,
respectively. The two main clusters (CLUST) predicted by the algorithm are labelled as blue and orange. In the heatmaps, CpG specific methylation b-
values were standardised to zero mean and unit variance for sake of clarity (blue: high relative methylation, yellow=low relative methylation). In
panels b) and c) we give the number of samples with active disease at sample draw in each cluster, and give the corresponding Fisher’s exact test P-
value. d) Comparison of observed P-values with those obtained by 1000 random selections of 293 CpGs. P-values were computed from Fisher’s exact
test for the two clusters inferred from applying a Gaussian mixture model [43].
doi:10.1371/journal.pone.0008274.g004
Peripheral Blood Methylation
PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8274Another related question is whether the diagnostic epigenetic
signature is specific to ovarian cancer. If different cancers elicit
similar immune responses and thus similar changes in blood cell
type composition, we could expect a proportion of the identified
diagnostic signature to be non-cancer specific. However, to
conclusively determine that this is the case and that age and
cancer are not mediating immuno-compromising effects via
epigenetic modification of particular cell-types, requires additional
data not provided by our study. Similarly, whether parts of the
observed cancer signatures may be causally involved in the disease
must await further investigations.
A second DNAm signature was characterised by CpGs
undergoing hypermethylation with age and was highly enriched
for developmental genes and REST-targets. Given that REST
(NRSF) is involved in suppression of genes that are required for
differentiation of embryonic and adult stem cells [24], the age-
induced hypermethylation of REST-targets, if confirmed in a stem-
cell population, may represent a generic mechanism for age-
associated loss of stem-cell function and increased predisposition to
cancer [5].
Finally, our finding that most of the methylation variability is
associated with niCpGs further supports the view that most of the
phenotypically relevant DNAm variation is to be found in regions
other than CpG islands [19]. Confirming this further, the observed
association between gene expression of different blood cell-types
and the pattern of DNA hypo and hypermethylation was much
stronger for niCpGs than iCpGs (data not shown).
In summary, this work demonstrates that DNAm profiling in
blood holds significant promise as a future diagnostic or risk-
prediction tool and warrants further higher CpG-coverage studies
to fully elucidate this role.
Materials and Methods
Description of UKOPS Sample Collection
A total of 540 whole blood samples were drawn from the UK
Ovarian Cancer Population Study (UKOPS) for inclusion in this
study. Cases (n=266) consisted of postmenopausal women
diagnosed with primary epithelial ovarian cancer. Half of the
cases (pre-treatment cases; n=131) gave their blood at the time of
their diagnosis prior to treatment and the other half (post-
treatment cases; n=135) gave their blood at some stage during
their follow up visits after primary treatment (2.462.7 years
between diagnosis and blood sample taken). Controls (n=274)
were apparently healthy postmenopausal women recruited from
the UK Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS) [34] for which annual serum samples are available.
Recruitment took place at 8 participating hospitals within the UK.
Women with a previous history of bilateral oophorectomy and/or
cancer were excluded from the study. All cases and healthy
controls were postmenopausal and age-matched and detailed
clinical characteristics are given in Table S1.
Sample Processing
Blood samples were collected by the study nurse at the regional
centres in tubes (9 mL K3 EDTA Vacuette tubes, manufactured
by Greiner Bio One) and were frozen within 3 hours of collection.
The samples were stored at 280uC at the regional centre and were
shipped to the central laboratory at UCL on a quarterly basis.
Once received in the central laboratory, the samples were logged
and transferred to 280uC freezer until the DNA was extracted.
Serum CA125 concentrations were determined by electrochemi-
luminescence sandwich immunoassay on an Elecsys 2010 (Roche
Diagnostics, Burgess Hill, UK) using two monoclonal antibodies
(OC125 and M11; Fujirebio Diagnostics AB, Go ¨teborg, Sweden),
and values .30 were taken as a marker of active disease [35].
Over 95% of pre-treatment cases had CA125.30, while among
post-treatment cases about 40% had active recurrent disease
(CA125.30).
DNA Extraction and Bisulphite Modification
The DNA was extracted at Tepnel, using a chloroform based
extraction method and 800 ng (26400 for each sample). Average
DNA concentration was 33.0617.4 ng/mL. DNA from each
sample was bisulphite modified using the EZ DNA Methylation
Kit D5008 (Zymo Research, Orange, CA, USA) according to the
manufacturer’s instructions.
Illumina Infinium Assay
Methylation analysis was performed using the Illumina Infinium
Human Methylation27 BeadChip. Briefly, bisulphite converted
DNA was amplified, fragmented and hybridised to the BeadChip
arrays (each chip accommodates 12 samples as designated by
Sentrix positions A–L). A single base extension was then
performed using labelled DNP- and biotin labelled dNTPs. The
arrays were imaged using a BeadArray
TM Reader. Image
processing and intensity data extraction were performed according
to Illumina’s instructions. Each interrogated locus is represented
by specific oligomers linked to two bead types: one representing
the sequence for methylated DNA (M) and the other for
unmethylated DNA (U). The methylation status of a specifc
CpG site is calculated from the intensity of the M and U alleles, as
the ratio of fluorescent signals b=Max(M,0)/[Max(M,0)+
Max(U,0)+100]. DNA methylation b values are continuous
variables between 0 (absent methylation) and 1 (completely
methylated) representing the ratio of combined locus intensity.
Experimental Design
A total of 540 samples (274 healthy, 131 pre-treatment, 135
post-treatment) and 12 controls (methylation control consisted of a
single pool of fully methylated Sss1 treated genomic DNA to
monitor for batch to batch variation) were hybridised to the
Illumina Infinium platform, distributed across 11 batches of 48
samples each (4 sentrix chips of 12 samples per batch) and 1 batch
of 24 (2 sentrix chips). Pre-treatment and post-treatment cases and
controls were randomised across batches and within each batch
across beadchips, and included an average of 29 cases and 17
healthy samples for batches 1–9. Due to logistic reasons there was
an over representation of controls in batches 10–12. Due to batch
effects, these were later excluded from statistical analysis to avoid
any bias.
Quality Control
Background corrected U & M values, b values (as generated
from the Beadstudio software) and built-in controls were used to
evaluate the quality of individual arrays. Samples with low
bisulphite (BS) conversion efficiency (BS control intensity values
,4000) were excluded, as well as other outliers that we detected
using boxplots of total intensity I=U+M values and histograms of
b-values. After this first QC step, 502 samples remained. Next,
samples were filtered further according to CpG coverage, using
the Beadstudio p-values of detection of signal above background.
Specifically, we computed the global (inter-sample) CpG coverage
for different minimum levels of CpG coverage per sample:
demanding at least 95% coverage per sample gave 93% global
coverage (25,642 CpGs) across 495 samples, resulting in a b-
valued data matrix of dimension 25,6426495.
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Given the b-valued data matrix over 495 samples and 25,642
CpG sites, we performed a singular value decomposition (SVD) to
determine the nature of the largest components of variation. SVD
has been successfully applied to methylation b-valued data before
[36]. We focused on the top 20 principal components and
correlated these to experimental factors, including batch, well
position, sentrix chip, BS conversion efficiency (as assessed using
the built-in BS conversion efficiency controls) and DNA input, as
well as phenotypic factors, including case control status. This
analysis showed that most of the variation was associated with
potentially confounding batch, DNA input and BS conversion
(BSC) efficiency effects, thus requiring careful inter-array normal-
isation procedures. Because three batches consisted overwhelm-
ingly of healthy control samples and thus were entirely
confounded, these were removed, yielding a b-matrix over
25,642 CpGs and 383 samples (148 healthy controls, 113
pretreatment samples, 122 postreatment samples) for further
analysis.
To perform the SVD analyses, imputation of missing b-valued
data was necessary and was accomplished using the k-nearest
neighbours procedure [37]. The missing b-values were caused by
probes with only a few good quality bead-level replicates, for
which therefore no b-values were reported. We verified however
that imputation gave almost identical values to the alternative
procedure of recalculating b-values from the bead-replicate
averaged U and M values, thus validating both imputation
approaches.
Inter-Array Normalisation
Normalisation across arrays was performed initially using a
variety of strategies: (a) do-nothing (b) separate quantile normal-
isation of the U and M channels and recomputation of b-values, (c)
quantile normalisation of b-values, (d) quantile normalisation
followed by adjustment for batch, DNA input and BSC efficiency
effects, and (e) adjustment for batch, DNA input and BSC
efficiency effects. The various strategies were evaluated in two
ways. First, we asked if the median b-values per sample were
strongly correlated with any of the unwanted factors such as BSC
efficiency. A more stringent evaluation was provided by a SVD to
check whether components of variation were correlated with
unwanted factors. The median-based analysis (and SVD) indicated
that methods (a) (Figure S1a) and (b) (not shown) were inadequate.
SVD also showed that quantile normalisation (method (c)) did not
remove all unwanted variation (Figure S1b). However, adjusting
the quantile normalised data for BSC efficiency, DNA input and
batch effects (method (d)), by appropriate inclusion of co-factors in
a multivariate regression model, we succeeded in peeling away
almost all of the unwanted variability (Figure S1c). Method (e) also
performed optimally and results did not vary appreciably between
methods (d) and (e) (not shown). After inter-array normalisation
using either method (d) or (e), the largest components of variation
were associated with phenotypic factors such as age and cancer
(Figure S1c).
Significance of Singular Values
The statistical significance of the components of variation
inferred using SVD was evaluated against the null distribution
obtained by considering random matrices. The normalised
adjusted data was randomised by permuting the CpGs, using a
distinct permutation for each sample. Subsequently, SVD was
performed on the randomised data matrix and the fraction of
variation of the inferred singular values compared to the fractions
of variation of the unpermuted data (Figure S2). We verified using
multiple randomised matrices that the null distribution of singular
values is very tight (Figure S2), allowing significance to be
estimated from as little as 5 permutations.
Supervised Analysis
Associations between CpG b-valued methylation profiles and
phenotypes of interest were carried out using robust linear
regressions for ordinal/continuous phenotypes (age) or logistic
regressions for binary phenotypes (case/control status). Multivar-
iate regressions were performed for each CpG separately and
included factors for batch, DNA input and BSC efficiciency
effects. To correct for multiple testing we estimated the false
discovery rate (FDR) using the q-value framework [38]. Since
CpG sites within the same CpG-island may exhibit similar
methylation profiles, and given that 7,528 CpG islands contained
more than one CpG site, we also estimated the FDR using a
permutation approach that would take the correlations of CpG
sites into account. Specifically, sample labels were permuted (same
permutation over all CpGs) and supervised analyses carried out on
the resampled data set, using a total of 100 permutations to obtain
reasonable estimates of the FDR. We found however that FDR
estimates using the permutation approach were very similar to
those estimated using the q-value framework at the significance
levels of relevance (Figure S3). The q-value method was thus
adopted for computational convenience. FDR estimates were
further confirmed with Surrogate Variable Analysis (SVA) [31,32].
SVA allows more accurate FDR estimates to be obtained by
including potentially hidden (i.e unknown) in addition to known
confounding factors in the multivariate regression [31,32]. SVA
models the known and hidden confounding factors using a SVD
on the residual variation matrix that remains after regression of the
b-matrix to the phenotype of interest, and generally yields a more
accurate FDR estimate [31,32].
Classification Analysis
The following strategy was used to determine whether a DNA
methylation signature from peripheral blood could be used to
predict the presence of the tumour. (1) A training set of 90 healthy
controls and 70 pretreatment (preT) cases was selected at random.
(2) Using the training set, a multivariate logistic regression of case
control status against the b profile of a CpG site was performed for
each of the 25,642 CpG sites and adjusting for BSC efficiency,
DNA input and batch effects. (3) CpG sites were ranked according
to the magnitude of the regression coefficient and associated p-
values of significance. (4) p-values were transformed into q-values
[38] to provide an estimate of the false discovery rate (FDR). (5)
Using the top 1000 CpGs (these all passed a 0.05 FDR threshold)
we then applied a nearest shrunken centroid classifier [39] to
obtain methylation centroids for cases and controls. Optimal
classifier performance as a function of the degree of shrinkage
(number of CpG sites) was monitored and an optimal (or near
optimal) classifier selected based on the top 100 CpG sites. (6)
Next, using this centroid classifier we computed the posterior
probability for each sample in the blind test set (58 healthy & 43
preT) to be a case. Thus, the probability of cancer status can be
viewed as a continuous predictor and performance evaluated using
ROC and AUC measures. (7) This analysis was repeated for 100
different training test set partitions and the average AUC and 95%
confidence interval envelopes in the training and test sets was
recorded.
Clustering of Methylation Profiles
Age-associated CpGs were derived from the 148 healthy control
samples using the previously described supervised analysis (293
Peripheral Blood Methylation
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healthy controls and 113 preT cases were then clustered over these
293 CpGs using a hierarchical clustering algorithm with Pearson
correlation metric and average linkage. Prior to clustering, CpG b-
profiles were standardised to mean zero and unit variance across
samples. The same clustering procedure was applied to the 122
post-treatment samples, of which 117 had CA125 serum level data
at the time of sample draw. Dendrograms were cut to yield two
main clusters to highlight the clustering of samples with active
disease (i.e preT or posT with CA125.30) and without active
disease (i.e healthy samples or post with CA125,30). Non-
random associations of disease status with the two main clusters
were tested using two-tailed Fisher’s exact test. To establish the
significance of the clustering in relation to all CpGs found on the
array, 1000 random selections of 293 CpGs were performed and
samples reclustered. A P-value of significance was then obtained
by estimating the fraction of times (out of 1000) that the Fisher-test
P-value was as extreme as the observed one.
Gene Set Enrichment Analysis
Given a list of CpGs, these were mapped to promoters and
unique gene loci and then tested for enrichment of biological terms
and pathways using the Gene Set Enrichment Analysis (GSEA)
and the Molecular Signatures Database (MSigDB) tool [22].
Significant associations were confirmed with an independent
method, EASE [40].
Software
All computations and statistical analyses were performed using
R 2.8.1 (http://www.r-project.org) [41] and Bioconductor 2.3
(http://www.bioconductor.org) [42].
Supporting Information
Figure S1 Diagnostic SVD analysis: Heatmap of p-values of
association between the top 20 singular vectors (principal
components) from the singular value decomposition (SVD) of
the beta-valued data matrix and phenotypic as well as experi-
mental factors. Phenotypic factors included case control status
(coded as 0,1), stage of cancer (0=stage1 or 2, 1=stage3 or 4),
grade (1,2,3), histological subtype (clear cell, endometriod, serous,
other) and age at sample draw coded as (1=50–55, 2=55–60,
3=60–65, 4=65–70, 5=70–75, 6=75+). Experimental factors
included bisulphite conversion efficiency controls (BSC1 & BSC2),
DNA input and batch number. P-values coded as follows: P,10e-
10 (darkred), 10e-10,P,10e-5 (red), 10e-5,P,0.01 (orange),
0.01,P,0.05 (pink), P.0.05 (white). a) Before inter-array
quantile normalisation, b) After inter-array quantile normalisation.
c) After adjustment for BSC, DNA input and batch effects.
Found at: doi:10.1371/journal.pone.0008274.s001 (0.03 MB
PDF)
Figure S2 Significance analysis of singular values: Statistical
significance analysis of singular values inferred from an SVD
decomposition of the normalised adjusted data. x-axis denotes
singular values ranked according to magnitude of variation. y-axis
denotes the fraction of variation in the data explained by that
singular value. Red points show the observed fractions, black
points denote the fractions of variation under a random reshuffling
of the data [Leek et al. 2008]. There are approximately 11
significant components of variation explaining about 24% of the
variation in the data.
Found at: doi:10.1371/journal.pone.0008274.s002 (0.02 MB
PDF)
Figure S3 FDR estimation using permutation of sample labels:
Top diagram plots the sorted log10(pvalues) (y-axis) of association
with cancer (from logistic regression) against CpG index (x-axis).
Black denotes observed p-values, green denotes corresponding
values obtained after permutation of sample labels. Lower diagram
compares the estimated mean number of false positives (y-axis)
against the number of positives (x-axis) (i.e., the number of tests
passing a given significance threshold). In blue, we show the
estimate from the permutation approach; in red, the analytical
estimate from the q-value. At an FDR,0.05 both methods predict
a similar number of significant CpGs.
Found at: doi:10.1371/journal.pone.0008274.s003 (3.86 MB
PDF)
Figure S4 DNA methylation levels of granulocyte and lmpho-
cyte markers: Average methylation levels (y-axis) of CpGs
mapping to genes upregulated in granulocytes and lymphocytes
against different disease states: H (healthy control samples,
n=148), CA125- (post-treatment cases with CA125,30, n=70),
CA125+ (post-treatment cases with CA125.30, n=47). P-values
from two-tailed Wilcoxon-tests between H and CA125- and
between H and CA125+ are shown.
Found at: doi:10.1371/journal.pone.0008274.s004 (0.01 MB
PDF)
Figure S5 Age-dependent methylation patterns are associated
with ovarian cancer: a–b) Average methylation patterns of age
anti-correlated niCpGs selected through supervised analysis.(a)
Average methylation versus age group for controls and cases. (b)
Average methylation versus disease status. c–d) Average methyl-
ation patterns of age correlated niCpGs selected through
supervised analysis.(c) Average methylation versus age group for
controls and cases. (d) Average methylation versus disease status.
e–f) Average methylation patterns of age anti-correlated iCpGs
selected through supervised analysis.(e) Average methylation
versus age group for controls and cases. (f) Average methylation
versus disease status. g–h) Average methylation patterns of age
correlated iCpGs selected through supervised analysis.(g) Average
methylation versus age group for controls and cases. (h) Average
methylation versus disease status. In panels b,d,f,h, p-values are
from a two-tailed Wilcoxon rank sum test (0=controls, 1=case).
In panels a,c,e,g, we give the numbers of samples in each age
group and P-values reflect strength of the linear regression. Age
groups are coded as (1=50 to 55, 2=55–60, 3=60–65, 4=65–
70, 5=70–75, 6=over75). Cases are pretreatment samples.
Found at: doi:10.1371/journal.pone.0008274.s005 (0.05 MB
PDF)
Figure S6 Derivation of cancer predisposition/risk CpGs: a)
Histogram of p-values from multivariate logistic regression models
(MVLR) comparing cancer status of postreatment patients without
active disease at sample draw (70 samples) with age-matched
healthy controls (148 samples). Logistic regression models included
cancer status as a binary response and the CpG methylation
profile as a predictor with batch, bisulphite conversion and DNA
input as co-factors. Histogram distribution is relatively flat
indicating the absence of discriminatory CpGs. Using Surrogate
Variable Analysis (SVA+MVLR) to model all confounding known
and hidden factors, p-value distribution exhibits a skew towards
significant p-values, suggesting the existence of discriminatory
CpGs. b) To deconvolute the effects of tumor-presence and
treatment, cancer predisposition or risk CpGs should be given by
the overlap of cancer-diagnostic CpGs with the 84 CpGs (FDR
(q),0.4) that discriminate postreatment cases without active
disease (AD) from healthy controls. This yielded 18 candidate
ovarian cancer risk CpGs.
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PDF)
Table S1 Clinical characteristics of samples.
Found at: doi:10.1371/journal.pone.0008274.s007 (0.06 MB
PDF)
Table S2 List of cancer diagnostic CpGs (CA-CpGs).
Found at: doi:10.1371/journal.pone.0008274.s008 (0.58 MB
PDF)
Table S3 Summary of Gene Set Enrichment Analysis results on
CpGs in blood undergoing significant hyper- and hypomethylation
with age and with presence of ovarian cancer.
Found at: doi:10.1371/journal.pone.0008274.s009 (0.06 MB
XLS)
Table S4 Enrichment analysis of genes undergoing age and
cancer specific DNAm changes and genes upregulated in major
blood cell-types.
Found at: doi:10.1371/journal.pone.0008274.s010 (0.01 MB
XLS)
Table S5 Discriminatory CpGs between postreatment samples
without active disease and healthy controls.
Found at: doi:10.1371/journal.pone.0008274.s011 (0.04 MB
PDF)
Table S6 Gene Set Enrichment Analysis of genes differentially
expressed between major blood cell types.
Found at: doi:10.1371/journal.pone.0008274.s012 (0.17 MB
XLS)
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